An observational study in Chronic Kidney Disease With and Without Hemodialysis, sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by Sohag University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Renal Insufficiency, Chronic with a site in Egypt — 23 open to participants now, 28 under way, 4 of them phase 3. Renal Insufficiency, Chronic · Egypt.
Among the 64 studies in Renal Insufficiency, Chronic with a site in Egypt, this one is the 6th largest by planned enrollment of the 20 observational ones that give a count, is one of 9 that started in 2026, is one of 20 observational ones, reaches primary completion later than 20 of the 27 other live ones, and was the 60th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →23 of the 64 studies in Renal Insufficiency, Chronic with a site in Egypt are open now. Recruiting first, the newest first:
Badr University · Sites in Egypt
Ages 36–58
Future University in Egypt · Sites in Egypt
Ages 18+
Ace Cells Lab Limited · Sites in Egypt
Ages 18–80
Sohag University · Sites in Egypt
Ages 18+
Ain Shams University · Sites in Egypt
Ages 18+
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 8 · Phase 4 8
First in 2013; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is close to the median of 213 across 835 observational studies indexed under Renal Insufficiency, Chronic.
Median enrollment 64 across the 44 interventional studies, 110 across the 20 observational. Of the 29 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 64 have an industry lead sponsor. The 10 most frequent:
Sohag University is the lead sponsor of 1,236 studies on the registry; 639 are open to participants now.
Sohag University has 7 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
6 of the studies in Renal Insufficiency, Chronic with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07706582Beni-Suef UniversityManagement of Iron Deficiency Anemia in Hemodialysis Patients | 2026-12 |
| NCT03436368Nazmy Edward SeifContinuous Spinal Anesthesia in Renal Transplantation | 2026-12 |
| NCT03778944Nazmy Edward SeifEnhancing Renal Graft Function During Donor Anesthesia | 2026-12 |
| NCT07640919Sohag UniversityPatterns of Cardiac Arrhythmia in Patients With Chronic Kidney Disease | 2026-12-20 |
| NCT07235891Alexandria UniversityRetinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease | 2026-12-20 |
Add all 6 to your calendar (.ics) → With an account.
Among the 64 studies in Renal Insufficiency, Chronic with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cardiovascular diseases remain the primary leading cause of death in patients on maintenance hemodialysis accounting for nearly 41% of deaths.
Chronic kidney disease is associated with an excess of acquired arrhythmia of multiple types, and atrial fibrillation in particular.
Sudden cardiac death is also more common in chronic kidney disease and accounts for around one- quarter of deaths in dialysis patients.
The aim of the study is to evaluate the incidence, describe the patterns of cardiac arrhythmia and to determine the factors predisposing to cardiac arrhythmia in patients with chronic kidney disease with or without hemodialysis.
After obtaining written, informed consents, individuals are subjected to thorough clinical evaluation (age, sex, history of hypertension (HTN) or diabetes mellitus (DM)) and laboratory tests including complete blood count, urea, creatinine, glomerular filtration rate (eGFR) (calculated by CKD-EPI equation) , serum potassium, magnesium, calcium, phosphorus, parathyroid hormone (PTH), iron and total iron binding capacity (TIBC).
Twelve-lead ECG is performed and all ECGs are reviewed for the following parameters: heart rhythm, heart rate, frontal axis, P wave, PR interval, QRS duration, pathological Q wave, fragmented QRS morphology, ST-segment deviation, QT interval and T wave abnormality.
Patients with chronic kidney disease at hemodialysis unit and outpatient nephrology clinic at Sohag university hospitals
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Detection of changes (already exsited) in heart rate (measured in beats/ minutes) and corrected QT interval (measured in milliseconds) from normal limits in patients with chronic kidney disease.
Twelve-lead ECG is performed and all ECGs are reviewed for the following parameters: * heart rate (measured by beats/minutes) normal limit: 60 - 100 b/m * corrected QT interval (measured in milliseconds) normal limit: 330 - 440 ms in males and 330 - 450 in female
Time frame: Health survey distributed during 4 months to determine how many patients with chronic kidney disease have cardiac arrhythmia in hemodialysis unit and outpatient nephrology clinic at sohag university hospitals
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Dec 2026, 5 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →